

FOR IMMEDIATE RELEASE

May 20, 2014

Methapharm Appointed as Canadian Distributor of Fucithalmic[®] Viscous Eye Drops

Amdipharm Mercury (AMCo) announced today that Methapharm has been appointed as their Canadian distributor for Fucithalmic[®] (fusidic acid) Viscous Eye Drops. Fucithalmic viscous eye drops are indicated for the treatment of superficial infections of the eye and its adnexa (ie., conjunctivitis) caused by fusidic acid susceptible strains of the designated bacteria in adults and children (≥ 2 years of age): Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae

About Amdipharm Mercury

Amdipharm Mercury (AMCo) is a rapidly growing international niche pharmaceuticals company delivering high quality niche medicines to patients and healthcare authorities in 112 countries. AMCo is the result of the merger in 2013 of Amdipharm and the Mercury Pharma Group by the private equity firm Cinven. The combined businesses are highly complimentary to each other, with well established product portfolios, and provide a strong platform for future growth through acquisitions in line with Cinven's ambition to build a truly global pharmaceutical company. Since the merger in early 2013, AMCo has acquired global rights to Fucithalmic[®] from LEO Pharma A/S and then acquired Abcur A/S in Sweden to create a direct presence in the Nordics, to complement its existing direct presence in the UK, Ireland, France and Benelux (see amcolimited.com/news).

About Methapharm

Methapharm, based in Brantford, Ontario and Coral Springs, Florida is a privately held, full-service specialty pharmaceutical and medical device company offering comprehensive in-market capabilities in either the USA or Canada. We are focused on the commercialization and marketing of specialty pharmaceutical products and medical devices. We are also an ISO 13485:2003 accredited facility.

For more information:

Chris Calenti
General Manager
Methapharm Inc.
Tel: (+1) 519-751-3602

www.methapharm.com